Lion's Mane for Dementia: What the Human Trials Actually Show

By Peter Orpen — Published: 26 April 2026 — Reviewed: 26 April 2026

Before We Start: What This Article Will and Won't Tell You

Lion's mane mushroom does not address dementia through supplementation. It has not demonstrated clinically meaningful benefit for Alzheimer's disease. It is not registered by the TGA as a therapeutic for any neurodegenerative condition. If you're reading this hoping to find a natural supplement in place of your neurologist's advice, this article will disappoint you in exactly the right way.

What it will give you is an honest account of two small human trials, one 2025 PRISMA systematic review, and a body of preclinical research that is genuinely interesting — and genuinely incomplete. The research on lion's mane and cognitive decline is real. It is also The Two-Trial Problem — we call this the central challenge in the dementia evidence base: two small studies, one in mild cognitive impairment and one in early Alzheimer's, conducted fifteen years apart, neither replicated at scale. That is the truth of where the evidence sits right now.

We think you deserve to know that before you spend a cent.

What Is Mild Cognitive Impairment — And Why It Matters Here

Mild cognitive impairment (MCI) is not Alzheimer's disease. It is the grey zone between normal age-related memory changes and confirmed dementia. People with MCI have measurable cognitive decline — on tests like the Hasegawa Dementia Scale (HDS-R) or the Mini-Mental State Examination (MMSE) — but can still manage their daily lives independently.

The distinction matters enormously for reading the research. The landmark Mori 2009 trial recruited adults with MCI, not Alzheimer's. The Li 2020 pilot recruited patients with mild Alzheimer's. These are different populations, different disease stages, and different expectations for what "improvement" looks like.

MCI does not inevitably progress to dementia. Roughly 10–15% of people with MCI do progress to Alzheimer's per year, but a meaningful proportion stabilise or even improve. This makes it an important intervention window — and also a population where natural variation can make small trials difficult to interpret.

The Mori 2009 RCT: The Landmark Trial — And Its Critical Limitation

The most cited human evidence for lion's mane and cognition is a 2009 double-blind, placebo-controlled randomised controlled trial by Mori et al. (PMID 18844328), published in Phytotherapy Research. It enrolled 30 Japanese adults aged 50–80 with mild cognitive impairment.

Participants in the active group took 3g/day of lion's mane dry powder — specifically, four 250mg tablets, three times daily — at doses used in studies across 16 weeks. The primary outcome was the Revised Hasegawa Dementia Scale (HDS-R), a validated cognitive assessment.

The result: significantly higher HDS-R scores in the lion's mane group at weeks 8, 12, and 16, compared to placebo. This is the figure that gets quoted on supplement websites. What gets omitted is what happened next.

Four weeks after stopping treatment — in the trial's post-dosing observation period — the lion's mane group's scores declined. Cognitive function returned toward baseline once supplementation stopped. The effect showed no benefit for cognitive scores once supplementation stopped. This is not a minor footnote. It suggests the compound does not modify the underlying disease process — it appears to support function only while being taken.

"A very small, double-blind, placebo-controlled trial in patients with mild cognitive impairment showed a temporary improvement in cognitive function; this finding has yet to be replicated."

The limitations are worth naming plainly: n=30, single-centre, Japanese cohort only, no biomarker confirmation, and — crucially — the key finding remains unreplicated.

The Li 2020 Pilot: 49 Weeks, Mild Alzheimer's, Industry-Funded

The second human trial is a 49-week pilot study by Li et al. (PMID 32581767), published in Frontiers in Ageing Neuroscience in 2020. It is registered on ClinicalTrials.gov (NCT04065061) and enrolled 49 patients with mild Alzheimer's disease — a meaningfully different population from Mori 2009.

Instead of whole mushroom dry powder, this trial used erinacine A-enriched Hericium erinaceus mycelia (EAHE) capsules — three 350mg capsules daily, standardised to 5mg/g erinacine A. The 49-week treatment period is the longest cognitive trial yet conducted with lion's mane.

The outcomes were measured across a battery of cognitive and biomarker assessments: CASI, MMSE, IADL scales, contrast sensitivity, diffusion tensor imaging (DTI), and blood biomarkers. Key findings:

• The placebo group showed significant decline in CASI scores; the EAHE group did not
• The EAHE group showed significant MMSE improvement over the trial period
• Diffusion tensor imaging showed parahippocampal cingulum changes favouring EAHE
• The placebo group lost significant levels of calcium, albumin, ApoE4, haemoglobin, and BDNF — the EAHE group did not show these declines

Four participants dropped out due to abdominal discomfort, nausea, and skin rash.

Two transparency points matter here. First, the status of NCT04065061 on ClinicalTrials.gov is listed as "Unknown" — the confirmatory Phase-3 trial has not progressed. Second, the study was funded by Grape King Bio Ltd, a Taiwanese supplement manufacturer. This does not invalidate the findings, but it warrants acknowledgement when interpreting them.

The trial did not demonstrate a disease-modifying effect on amyloid beta peptide 1-40 — neither group improved on this biomarker; the placebo group declined faster. This is stabilisation, not reversal.

The 2025 PRISMA Systematic Review: Putting a Number on It

In 2025, Menon, Jalal et al. published a PRISMA-guided systematic review (PMID 40959699, PROSPERO CRD42024571250) in Frontiers in Nutrition, aggregating 5 RCTs, 15 laboratory studies, 3 pilot clinical trials, 1 cohort study, and 1 case report on Hericium erinaceus.

For cognitive outcomes specifically — drawing on the Mori 2009 RCT and Li 2020 pilot — the review calculated a combined weighted mean MMSE increase of 1.17 points in the intervention group versus placebo.

That number deserves careful framing. A 1.17-point MMSE change is statistically observable. It is below the threshold typically cited as clinically meaningful — generally 1.4 points or more in Alzheimer's research. The authors of the underlying trials acknowledge this. The systematic review authors acknowledge this.

The review also summarised the proposed mechanisms: pro-BDNF (brain-derived neurotrophic factor) synthesis, hippocampal neurogenesis, and increased production of short-chain fatty acid-producing gut microbiota. These are plausible pathways. They are supported by substantial preclinical evidence. They have not yet been confirmed in adequately powered human trials.

How Lion's Mane Is Thought to Work: Mechanism Evidence (Mostly Preclinical)

The bioactive compounds in lion's mane most relevant to brain research are hericenones (from the fruiting body) and erinacines (from the mycelium). Both compound classes have demonstrated the ability to stimulate Nerve Growth Factor (NGF) synthesis and promote BDNF production in laboratory and animal models.

A 2025 PRISMA-guided systematic review by Spangenberg et al. (PMID 40626304) specifically reviewed erinacines across cellular and rodent models. Erinacine A and C uniquely induced Nrf2 transcription factor accumulation — a key regulator of antioxidant response. Both showed anti-inflammatory effects, enhanced neurogenesis, and improved cognitive outcomes in animal models. Effects were dose-dependent.

A 2021 animal study (PMID 34684662) in senescence-accelerated mice — a validated Alzheimer's model — found that erinacine A-enriched lion's mane mycelium at doses of 108, 215, and 431 mg/kg/day over 12 weeks produced dose-dependent improvements in passive and active avoidance learning and memory, alongside reductions in oxidative stress markers (iNOS, TBARS, 8-OHdG).

The critical framing: human evidence is limited to two small trials. The mechanistic picture comes predominantly from cell cultures and rodent models. The pathway from a petri dish to a clinical benefit in humans remains a significant leap — one that the research community has not yet bridged with large-scale replication.

Human Trials at a Glance

Honest Limitations: What the Evidence Does NOT Show

This section is not a caveat. It is the substance of the article. The limitations of the lion's mane dementia evidence base are significant and deserve to be stated plainly rather than buried in footnotes.

• Only two small human trials specifically on cognitive impairment exist. Mori 2009 (n=30) and Li 2020 (n=49) are the full clinical record on dementia and MCI. That is 79 participants combined.
• The finding has yet to be replicated. ALSUntangled #73 (PMID 38141002) states this explicitly: "this finding has yet to be replicated." Independent large-scale confirmatory trials have not been published.
• The effect did not persist after stopping. In Mori 2009, showed no benefit for cognitive scores once supplementation stopped. This means it is not modifying the underlying disease.
• Li 2020 did not demonstrate a disease-modifying effect on amyloid beta peptide 1-40 beyond preventing further decline. The confirmatory Phase-3 trial (NCT04065061) has not progressed.
• MMSE +1.17 is below the clinical significance threshold. The weighted mean improvement across both trials, as calculated by the 2025 PRISMA review (PMID 40959699), is 1.17 points — below the 1.4-point threshold typically considered clinically meaningful in Alzheimer's research.
• No difference between groups on some measures. Spangenberg 2025 (PMID 40626304) noted that at typical supplement doses, no difference between treatment and control was observed in some preclinical models — effects are dose-dependent and may not translate to standard supplement servings.
• Most mechanistic evidence is from animal and cell models. The erinacine-NGF/BDNF pathway is extensively studied in mice and cell cultures. Human mechanistic data remains limited.
• Li 2020 is industry-funded. Grape King Bio Ltd, which manufactures EAHE, sponsored the trial. This is disclosed in the paper and should be factored into interpretation.

Brandalise et al. 2023 (PMID 37233262), in a comprehensive bench-to-bedside review titled "How Far from the Shoreline?", concluded that there is an "urgent need to carry out further/wider clinical trials to prove the safety and efficacy of H. erinaceus supplementation." That framing — how far from the shoreline — captures where the research stands.

Safety Profile

The 2025 systematic review (PMID 40959699) assessed safety across all included studies. Overall, lion's mane is well tolerated. The most commonly reported adverse events were stomach discomfort, headache, and allergic reactions. In Li 2020, four participants dropped out due to abdominal discomfort, nausea, and skin rash.

One case of anaphylaxis has been reported following consumption of fresh lion's mane mushroom — not a supplement. People with known mushroom allergies should exercise caution. If you develop any adverse reaction, discontinue use and seek medical advice.

Drug interactions are not well characterised in human trials. Some preclinical data suggests possible antiplatelet activity. If you are taking anticoagulant or antiplatelet medications (such as warfarin, clopidogrel, or aspirin), discuss supplementation with your healthcare professional before starting. Caution is also warranted for those on immunosuppressant medications.

What This Means in Practice

The research on lion's mane and cognitive decline is real, early-stage, and honest in its own limitations. Here is how to translate that into practical decisions.

If you have a confirmed dementia status: You should discuss any supplementation with your neurologist or treating physician before starting. Lion's mane is not a substitute for prescribed medication and should not be used as one. The evidence does not support replacing conventional care.

If you are supporting a family member with MCI or early Alzheimer's: Consider raising the research with their healthcare team. The evidence is preliminary, but the safety profile is generally favourable. A practitioner who is familiar with the literature can help you weigh the potential benefit against any individual risk factors.

If you are taking lion's mane for cognitive support: Aim for consistency rather than expecting dramatic results. The Mori 2009 trial used doses of 3g/day in Mori 2009 for 16 weeks — and showed regression after stopping. If you start, you should plan to continue consistently rather than treating it as a short-term intervention. Begin with the dose that matches your product's extract concentration.

When not to rely on lion's mane alone: It is not appropriate as a standalone intervention for a confirmed condition. Evidence-based cognitive support includes sleep quality, cardiovascular health, regular exercise, and social engagement — all of which have stronger evidence for neuroprotection than any single supplement. Consider lion's mane as a potential complement to a broader lifestyle approach, not a replacement for one.

You can combine lion's mane with other evidence-based approaches. Some practitioners pair it alongside omega-3 fatty acids, which have separate evidence for BDNF support. Discuss with your healthcare professional whether a stacking approach is appropriate for your situation.

Not recommended for people who are pregnant or breastfeeding, as safety in these populations has not been studied. Avoid if you have a known mushroom allergy. If you're taking prescribed anticoagulant medications, consult your doctor before use — the interaction has not been formally studied.

Should You Consider Lion's Mane for Cognitive Support?

From Our Formulations: What We Test For

We think transparency about what is actually in a lion's mane supplement is relevant when you are evaluating brain health research. Here is what our current formulation data shows for our extract line.

Our lion's mane extract uses a dual-extract process — ethanol and water solvents — at a 10:1 concentration ratio (10kg of raw mushroom to 1kg of finished extract). This matters for cognitive applications. Water extraction pulls the immune-active beta-glucans. Ethanol extraction is required to release the terpenoid compounds — including hericenones and the precursors to erinacine activity. A water-only extract would miss a significant portion of the brain-relevant fraction.

Certificate of Analysis (batch C24051507, dated 15 May 2024) from our supplier Yes Herbs (Xi'an Lifewe, China) confirmed:

• Beta-glucan content: 31.7% (our specification requires ≥30% — this batch exceeds it by 1.7 percentage points)
• Heavy metals tested and within limits: Lead ≤3.0mg/kg, Arsenic ≤2.0mg/kg, Cadmium ≤1.0mg/kg, Mercury ≤0.1mg/kg
• Microbiology: E. coli negative, Salmonella negative
• GMO-free, moisture loss on drying 1.13%, ash content 2.85%

The extract line is sourced from China — which is the global standard for medicinal mushroom extract production, where the cultivation expertise and dual-extraction facilities are most established. If Australian provenance is important to you, our Australian Grown Lion's Mane Capsules are cultivated in Australia — though as a whole mushroom (1:1) rather than a concentrated extract, they contain different relative compound concentrations.

No lion's mane supplement on the Australian market has been studied in a clinical trial equivalent to Mori 2009 or Li 2020. The studies used Japanese and Taiwanese formulations. We can tell you what is in our product with verified batch data. Whether the effect observed in those trials extends to our formulation — at the same dose, in the same population — is not something we can claim.

Frequently Asked Questions

Continue Your Research

This article focuses on the specific dementia and Alzheimer's evidence. Lion's mane has a broader evidence base for other aspects of cognitive health that is worth exploring:

• Lion's Mane Benefits: What 571 Studies Actually Show — the complete evidence picture across all health areas
• How Lion's Mane Works: The NGF Pathway — mechanism deep-dive into hericenones, erinacines, and dual-extraction
• Lion's Mane Studies: What the Human Trials Actually Show — broader clinical evidence overview
• Lion's Mane for Seniors: The Strongest Human Evidence — adjacent demographic, related research
• Lion's Mane for Brain Fog — cognitive clarity evidence in healthy adults
• Lion's Mane Dosage Guide: Clinical Trial Doses, Extract Conversions & Timing
• Lion's Mane Side Effects: Safety Profile Review
• Lion's Mane: Fruiting Body vs Mycelium — relevant for understanding the two trial types
• How to Choose a Quality Lion's Mane Supplement in Australia
• The Science — Teelixir's evidence standards and sourcing philosophy